NM_000551.4(VHL):c.422A>G (p.Asn141Ser) AND Hereditary cancer-predisposing syndrome

Clinical significance:Uncertain significance (Last evaluated: Sep 13, 2016)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
1 submission [Details]
Record status:

Allele description [Variation Report for NM_000551.4(VHL):c.422A>G (p.Asn141Ser)]

NM_000551.4(VHL):c.422A>G (p.Asn141Ser)

LOC107303340:3p25 von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase Alu-mediated recombination region [Gene]
VHL:von Hippel-Lindau tumor suppressor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_000551.4(VHL):c.422A>G (p.Asn141Ser)
  • NC_000003.12:g.10146595A>G
  • NG_008212.3:g.9961A>G
  • NG_046756.1:g.4357A>G
  • NM_000551.3:c.422A>G
  • NM_000551.4:c.422A>GMANE SELECT
  • NM_001354723.2:c.*18-3192A>G
  • NM_198156.3:c.341-3192A>G
  • NP_000542.1:p.Asn141Ser
  • NP_000542.1:p.Asn141Ser
  • LRG_322t1:c.422A>G
  • LRG_322:g.9961A>G
  • LRG_322p1:p.Asn141Ser
  • NC_000003.11:g.10188279A>G
  • NC_000003.11:g.10188279A>G
Protein change:
dbSNP: rs1064796570
NCBI 1000 Genomes Browser:
Molecular consequence:
  • NM_001354723.2:c.*18-3192A>G - intron variant - [Sequence Ontology: SO:0001627]
  • NM_198156.3:c.341-3192A>G - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000551.3:c.422A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_000551.4:c.422A>G - missense variant - [Sequence Ontology: SO:0001583]


Hereditary cancer-predisposing syndrome
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
MONDO: MONDO:0015356; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV000675823Ambry Geneticscriteria provided, single submitter
Uncertain significance
(Sep 13, 2016)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot provided1not providedclinical testing

Details of each submission

From Ambry Genetics, SCV000675823.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testingnot provided


The p.N141S variant (also known as c.422A>G), located in coding exon 2 of the VHL gene, results from an A to G substitution at nucleotide position 422. The asparagine at codon 141 is replaced by serine, an amino acid with highly similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.005% (greater than 20000 alleles tested) in our clinical cohort. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknown1not providednot provided1not providednot providednot provided

Last Updated: Oct 25, 2021

Support Center